Cover Story ______________________________________________________________________________________________________
recent US launch of Enoby and Xtrenbo – two denosumab biosimilars developed in partnership with Gedeon Richter. Under a licensing agreement, Gedeon Richter handles manufacturing while Hikma leads commercialization and regulatory compliance. It’ s a partnership built on complementary strengths, with the shared goal of getting high-quality medicine to patients faster.”
Balancing portfolio expansion with technical depth and expertise is a priority for Hikma, as demand grows for more complex and specialized medicines. To achieve this, the company is looking at more complex injectables – a high value segment requiring advanced expertise and innovation, as Natheer elaborates:“ Our approach involves building internal capabilities through organic development, and strategic partnerships
46